Abstract
Women frequently seek gynaecologic medical advice at menopause and require pharmacologic interventions to control subjective vasomotor complaints and to prevent late severe organic complications, which may effect the genitourinary tract, the skeletal, the cardiovascular and the nervous system. Depending on the severity of the presentation and the involvement of additional systems beyond the reproductive tract, physicians have several distinct therapies available, which should be carefully evaluated and administered in a “patient-personalised” fashion: they include organoriented drugs, available for selective treatment in patients which do not display major direct endocrine symptoms, as well as endocrine therapies (administration of native estrogens; or synthetic selective hormonal drugs, i.e. SERMs and SEEMs). Much interest is now focusing on new kinds of plant estrogen-like compounds, mostly isoflavones, which by one hand display estrogen-like (or antagonistic) effects, by the other are powerful antioxidising agents. In our survey, we discuss extensively the enormous amount of data available in the literature, underlining by one side that most of the formulations currently in use for the overall therapy of menopausal complaints have structure features also characteristic of antioxidising agents, by the other that there are wide evidences of increased oxidative damage occurs in women during the postmenopausal life. These observations suggest the possibility of a contribution of antioxidising activity of the administered drugs to the beneficial clinical effects on the patients, in agreement with the demonstrated estrogen intrinsic antioxidising activity in vitro. This stresses the requirement of further basic and clinical studies on the relevance of oxidative damage during postmenopausal female life.
Keywords: menopause, climacteric syndrome, hormone therapy, serm, seem, phytoestrogens, oxidative damage
Current Pharmaceutical Design
Title: Management of the Menopausal Disturbances and Oxidative Stress
Volume: 11 Issue: 16
Author(s): Francesco Pansini, Gioacchino Mollica and Carlo M. Bergamini
Affiliation:
Keywords: menopause, climacteric syndrome, hormone therapy, serm, seem, phytoestrogens, oxidative damage
Abstract: Women frequently seek gynaecologic medical advice at menopause and require pharmacologic interventions to control subjective vasomotor complaints and to prevent late severe organic complications, which may effect the genitourinary tract, the skeletal, the cardiovascular and the nervous system. Depending on the severity of the presentation and the involvement of additional systems beyond the reproductive tract, physicians have several distinct therapies available, which should be carefully evaluated and administered in a “patient-personalised” fashion: they include organoriented drugs, available for selective treatment in patients which do not display major direct endocrine symptoms, as well as endocrine therapies (administration of native estrogens; or synthetic selective hormonal drugs, i.e. SERMs and SEEMs). Much interest is now focusing on new kinds of plant estrogen-like compounds, mostly isoflavones, which by one hand display estrogen-like (or antagonistic) effects, by the other are powerful antioxidising agents. In our survey, we discuss extensively the enormous amount of data available in the literature, underlining by one side that most of the formulations currently in use for the overall therapy of menopausal complaints have structure features also characteristic of antioxidising agents, by the other that there are wide evidences of increased oxidative damage occurs in women during the postmenopausal life. These observations suggest the possibility of a contribution of antioxidising activity of the administered drugs to the beneficial clinical effects on the patients, in agreement with the demonstrated estrogen intrinsic antioxidising activity in vitro. This stresses the requirement of further basic and clinical studies on the relevance of oxidative damage during postmenopausal female life.
Export Options
About this article
Cite this article as:
Pansini Francesco, Mollica Gioacchino and Bergamini M. Carlo, Management of the Menopausal Disturbances and Oxidative Stress, Current Pharmaceutical Design 2005; 11 (16) . https://dx.doi.org/10.2174/1381612054065819
DOI https://dx.doi.org/10.2174/1381612054065819 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review
Current Cardiology Reviews Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Editorial (Thematic Issue: Advances in Drug Discovery for the Treatment of Cancer: Many Approaches, One Goal)
Current Topics in Medicinal Chemistry Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Approaches and Recent Trends in Gene Delivery for Treatment of Atherosclerosis
Recent Patents on Drug Delivery & Formulation The Role of Redox Dysregulation in the Inflammatory Response to Acute Myocardial Ischaemia-reperfusion Injury - Adding Fuel to the Fire
Current Medicinal Chemistry Lappaconitine: Influence of Halogen Substituent on the Antiarrhythmic Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations
Current Medicinal Chemistry Anaemia, Polycythaemia and Chronic Heart Failure
Current Cardiology Reviews Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Dietary Regulation of Glucose Metabolism in Metabolic Syndrome
Current Vascular Pharmacology Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Potential Therapeutic Effects of Physical Exercise for Bipolar Disorder
CNS & Neurological Disorders - Drug Targets Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry A Study of Prescription Pattern and Compliance of Anti-hypertensives with the Treatment Guidelines in Aseer Region; Saudi Arabia
Current Drug Therapy Screening Haemostasis – Looking for Global Assays: The Overall Haemostasis Potential (OHP) Method – A Possible Tool for Laboratory Investigation of Global Haemostasis in Both Hypo- and Hypercoagulable Conditions
Current Vascular Pharmacology Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Editorial (Thematic Issue: Health Impact and Management of a Disrupted Circadian Rhythm and Sleep in Critical Illnesses)
Current Pharmaceutical Design Mineralocorticoid Receptor Antagonism and Cardiac Remodeling in Ischemic Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents